# Adicet Bio

Source: https://onco.cc/companies/adicet-bio/  
OnCo record `adicet-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adicet makes off-the-shelf immune cell therapies from donor gamma delta T cells, a rarer type of T cell. Its lead programme is now aimed at lupus and other autoimmune diseases, with a prostate cancer candidate expected to enter the clinic in late 2026.

## Summary

Adicet Bio is a clinical-stage company developing allogeneic gamma delta T-cell therapies engineered with chimeric antigen receptors. Lead product prulacabtagene leucel (prula-cel, formerly ADI-001) is an allogeneic gamma delta CAR T candidate now developed primarily in autoimmune disease (lupus nephritis, systemic lupus erythematosus, systemic sclerosis, vasculitis and rheumatoid arthritis), with a phase 1 update and pivotal trial planning under way in 2026 after FDA alignment on outpatient dosing. In oncology, ADI-212 is a preclinical candidate for metastatic castration-resistant prostate cancer with a regulatory filing planned for the third quarter of 2026 and enrolment expected in the fourth quarter. Adicet is also building an in vivo CAR T platform for haematological malignancies and solid tumours. It completed a one-for-16 reverse stock split in December 2025 and trades on Nasdaq as ACET.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Redwood City, CA
- Type: cell-therapy
- Website: https://www.adicetbio.com/
- Ticker: ACET

## Notes

- Pipeline is now led by autoimmune indications; oncology exposure is ADI-212 (prostate) and an in vivo CAR T platform. No funding round sourced.

## Sources

- Official website: https://www.adicetbio.com/
- Q2 2026 results (8-K exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1720580/000172058026000049/acet-ex99_1.htm
- January 2026 corporate update (8-K exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1720580/000119312526005486/acet-ex99_1.htm

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- drugs: [ADI-270](https://onco.cc/drugs/adi-270/)

---
JSON: https://onco.cc/api/v1/entities/adicet-bio.json